Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2019 | 1 |
2021 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.
Viruses. 2018 Jan 21;10(1):48. doi: 10.3390/v10010048.
Viruses. 2018.
PMID: 29361733
Free PMC article.
Review.
Reversible disruption of XPO1-mediated nuclear export inhibits respiratory syncytial virus (RSV) replication.
Mathew C, Tamir S, Tripp RA, Ghildyal R.
Mathew C, et al.
Sci Rep. 2021 Sep 28;11(1):19223. doi: 10.1038/s41598-021-98767-2.
Sci Rep. 2021.
PMID: 34584169
Free PMC article.
Item in Clipboard
Immunogenicity and protective efficacy of an RSV G S177Q central conserved domain nanoparticle vaccine.
Bergeron HC, Murray J, Juarez MG, Nangle SJ, DuBois RM, Tripp RA.
Bergeron HC, et al.
Front Immunol. 2023 Jun 29;14:1215323. doi: 10.3389/fimmu.2023.1215323. eCollection 2023.
Front Immunol. 2023.
PMID: 37457705
Free PMC article.
Item in Clipboard
Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication In Vitro.
Jorquera PA, Mathew C, Pickens J, Williams C, Luczo JM, Tamir S, Ghildyal R, Tripp RA.
Jorquera PA, et al.
J Virol. 2019 Feb 5;93(4):e01684-18. doi: 10.1128/JVI.01684-18. Print 2019 Feb 15.
J Virol. 2019.
PMID: 30541831
Free PMC article.
Item in Clipboard
Cite
Cite